BioCentury
ARTICLE | Company News

American Biogenetic, Trevigen Inc. deal

April 20, 1998 7:00 AM UTC

MABXA will produce four mouse monoclonal antibodies for Trevigen using MABXA's Antigen Free technology, which uses mice that have had no prior exposure to antigens. Trevigen will use the antibodies in its diagnostic tests and screening assays relating to DNA mutations and apoptosis. MABXA will receive an upfront payment and is eligible for milestones and a 5 percent royalty. ...